Oppenheimer set a $67.00 target price on Biohaven Pharmaceutical (NYSE:BHVN) in a research note published on Wednesday, TipRanks reports. The firm currently has a buy rating on the stock.
BHVN has been the subject of a number of other research reports. Canaccord Genuity set a $80.00 price objective on Biohaven Pharmaceutical and gave the stock a buy rating in a research report on Monday, August 26th. William Blair reiterated a buy rating on shares of Biohaven Pharmaceutical in a research report on Tuesday, September 17th. Zacks Investment Research cut Biohaven Pharmaceutical from a buy rating to a hold rating in a research report on Friday, July 19th. Cantor Fitzgerald set a $87.00 price objective on Biohaven Pharmaceutical and gave the stock a buy rating in a research report on Wednesday, September 4th. Finally, Goldman Sachs Group set a $89.00 price objective on Biohaven Pharmaceutical and gave the stock a buy rating in a research report on Wednesday, September 4th. Four research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus price target of $69.27.
Biohaven Pharmaceutical stock opened at $43.01 on Wednesday. The stock has a market cap of $2.17 billion, a PE ratio of -6.99 and a beta of 0.32. The stock has a 50-day moving average price of $42.37 and a 200 day moving average price of $49.16. Biohaven Pharmaceutical has a 52 week low of $29.17 and a 52 week high of $67.86.
Biohaven Pharmaceutical (NYSE:BHVN) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($2.35) EPS for the quarter, missing analysts’ consensus estimates of ($2.09) by ($0.26). Equities research analysts predict that Biohaven Pharmaceutical will post -7.51 EPS for the current fiscal year.
In other Biohaven Pharmaceutical news, Director Eric Aguiar sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $45.00, for a total value of $450,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Gregory Bailey purchased 5,000 shares of the firm’s stock in a transaction on Tuesday, August 20th. The stock was acquired at an average cost of $37.65 per share, for a total transaction of $188,250.00. Following the completion of the purchase, the director now owns 2,587,601 shares in the company, valued at approximately $97,423,177.65. The disclosure for this purchase can be found here. 23.90% of the stock is currently owned by company insiders.
A number of large investors have recently modified their holdings of BHVN. Tower Research Capital LLC TRC acquired a new stake in Biohaven Pharmaceutical in the 2nd quarter worth about $65,000. Aperio Group LLC acquired a new stake in Biohaven Pharmaceutical in the 2nd quarter worth about $71,000. Glen Harbor Capital Management LLC boosted its stake in Biohaven Pharmaceutical by 165.9% in the 2nd quarter. Glen Harbor Capital Management LLC now owns 1,744 shares of the company’s stock worth $76,000 after buying an additional 1,088 shares during the last quarter. Canton Hathaway LLC acquired a new position in shares of Biohaven Pharmaceutical in the 3rd quarter valued at about $83,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Biohaven Pharmaceutical by 94.7% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,256 shares of the company’s stock valued at $99,000 after purchasing an additional 1,097 shares in the last quarter. 90.90% of the stock is currently owned by hedge funds and other institutional investors.
About Biohaven Pharmaceutical
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.
Featured Story: The risks of owning bonds
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.